Autres langues VYNE Therapeutics Inc.

Actions

VYNE

US92941V3087

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
2,47 ^USD	-3,89 %		+7,39 %	+6,01 %

04/04	Transcript : VYNE Therapeutics Inc. - Special Call
29/02	VYNE Therapeutics Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	19/03
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	29/02
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update	29/02
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium	27/02
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	21/02
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo	10/01
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	10/01
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors	03/01
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors	03/01
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	13/11
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	13/11
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023	07/11
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million	01/11
VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors	01/11
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	30/10/23
Investors Look Ahead to FOMC Meeting, Earnings Reports as US Futures Trend Higher Monday	30/10/23
Top Premarket Gainers	30/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues VYNE Therapeutics Inc.

Actions

VYNE

US92941V3087

Autres langues

Filtres